BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, November 26, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Fujian Akeylink Biotechnology identifies new Mpro inhibitors for SARS-CoV-2 infection
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Infection
Fujian Akeylink Biotechnology identifies new Mpro inhibitors for SARS-CoV-2 infection
July 20, 2023
No Comments
Fujian Akeylink Biotechnology Co. Ltd. has prepared short peptide compounds containing β-aminoketone and characterized as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors.
BioWorld Science
Infection
Coronavirus
Patents
